Denmark's Lundbeck is in for the best year in the company’s history, according to CEO Kåre Schultz who kicked off the year with a guidance hike and revenue of more than USD 150 million. “We do not need any mysteries or miracles. We just need to stay focused,” he says.
BY LONNI LYNGE Offentliggjort 10.05.17 kl. 21:17
Log ind for at læse artikler
Velkommen til MedWatch. En del af vores indhold er eksklusivt og forbeholdt vores brugere.
Novo Nordisk's major pipeline hope semaglutide has bested pretty much every major diabetes drug on the market in head-to-head studies, says CSO Mads Krogsgaard Thomsen. But the group will still have to beat out two more products before the GLP-1 analogue can be seen as the king of the clinic.
The average monthly salary in the private pharmaceutical industry in Denmark is DKK 57,109. Make the jump to find out which company pays the highest wages and learn how much the rest of the industry pays as well.
Zealand Pharma has listed on the Nasdaq Global Select Market in addition to its listing in Copenhagen, raising USD 89 in the process. But the move does not mean the biotech company has lost faith in the Danish investor base, says CEO Britt Meelby Jensen.
Genmab’s Darzalex royalties now cover the company’s operating costs and in addition to that, the cancer drug continues its expansion to new markets. And according to CEO, Jan van de Winkel, Genmab could potentially raise its guidance this year.
Danish medtech group Ambu continues to grow its revenue and earnings and that development might accelerate further. The biggest single investment in the company’s history is meant to ensure that, says CEO Lars Marcher.
Britiske AstraZeneca har endnu engang investeret et markant millionbeløb i et selskab, der udvikler lægemidler baseret på en særlig del af menneskets arvemateriale, som kan få kroppen til selv at danne proteiner med terapeutisk potentiale.
Den danske medicokoncern Ambu oplever stadigt stigende vækstrater, som selskabet endda vil løfte yderligere. Det skal blandt andet ske med den måske største enkeltinvestering i Ambus historie, siger adm. direktør Lars Marcher.